Company overview
Dolomite Microfluidics specializes in high-performance microfluidic systems for producing precision-engineered nano- and microparticles used in biomedicine, drug encapsulation, and delivery. Their platforms enable scalable droplet and particle generation with high monodispersity and batch consistency for pharmaceutical R&D. Key products include the Telos system for high-throughput processing and custom glass chips for applications like cell encapsulation and biological molecule separation.
Dolomite Product Line - End of Support is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include microfluidics, nanoparticles, microparticles, drug encapsulation, telos system.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://dolomite-microfluidics.com
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- microfluidics, nanoparticles, microparticles, drug encapsulation, telos system
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What microfluidic capabilities does Dolomite offer for pharma R&D?
- Dolomite provides systems for nano/microparticle synthesis, droplet generation, drug encapsulation, and high-throughput production using platforms like Telos for scalable emulsions and particles with precise size control.
- Can Dolomite support custom designs and regulatory needs?
- Yes, they offer custom chip designs up to 150 mm channels, 3D-printed interfaces, and process optimization for biomedical and pharmaceutical applications including drug delivery.
- What geographies does Dolomite serve?
- Dolomite has offices in the UK, US, and Japan with global distributors serving universities, chemical manufacturers, life sciences, and clinical diagnostics clients worldwide.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
